Logo image of AVRO

AVROBIO INC (AVRO) Stock Fundamental Analysis

USA - NASDAQ:AVRO - US05455M1009 - Common Stock

1.4 USD
-0.02 (-1.41%)
Last: 6/20/2024, 8:00:00 PM
1.45 USD
+0.05 (+3.57%)
After Hours: 6/20/2024, 8:00:00 PM
Fundamental Rating

3

Overall AVRO gets a fundamental rating of 3 out of 10. We evaluated AVRO against 533 industry peers in the Biotechnology industry. While AVRO has a great health rating, there are worries on its profitability. AVRO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year AVRO has reported negative net income.
AVRO had a negative operating cash flow in the past year.
In the past 5 years AVRO reported 4 times negative net income.
In the past 5 years AVRO always reported negative operating cash flow.
AVRO Yearly Net Income VS EBIT VS OCF VS FCFAVRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of 32.82%, AVRO belongs to the top of the industry, outperforming 99.65% of the companies in the same industry.
Looking at the Return On Equity, with a value of 34.11%, AVRO belongs to the top of the industry, outperforming 98.60% of the companies in the same industry.
Industry RankSector Rank
ROA 32.82%
ROE 34.11%
ROIC N/A
ROA(3y)-49.45%
ROA(5y)-45.78%
ROE(3y)-65.96%
ROE(5y)-56.84%
ROIC(3y)N/A
ROIC(5y)N/A
AVRO Yearly ROA, ROE, ROICAVRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AVRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVRO Yearly Profit, Operating, Gross MarginsAVRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for AVRO has been increased compared to 1 year ago.
AVRO has more shares outstanding than it did 5 years ago.
AVRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AVRO Yearly Shares OutstandingAVRO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
AVRO Yearly Total Debt VS Total AssetsAVRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

AVRO has an Altman-Z score of 2.61. This is not the best score and indicates that AVRO is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of AVRO (2.61) is better than 74.48% of its industry peers.
There is no outstanding debt for AVRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.61
ROIC/WACCN/A
WACCN/A
AVRO Yearly LT Debt VS Equity VS FCFAVRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 26.17 indicates that AVRO has no problem at all paying its short term obligations.
AVRO has a better Current ratio (26.17) than 95.98% of its industry peers.
A Quick Ratio of 26.17 indicates that AVRO has no problem at all paying its short term obligations.
The Quick ratio of AVRO (26.17) is better than 95.98% of its industry peers.
Industry RankSector Rank
Current Ratio 26.17
Quick Ratio 26.17
AVRO Yearly Current Assets VS Current LiabilitesAVRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 49.57% over the past year.
EPS 1Y (TTM)49.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 16.25% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y69.01%
EPS Next 2Y37.49%
EPS Next 3Y25.45%
EPS Next 5Y16.25%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AVRO Yearly EPS VS EstimatesAVRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AVRO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AVRO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVRO Price Earnings VS Forward Price EarningsAVRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVRO Per share dataAVRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

AVRO's earnings are expected to grow with 25.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.49%
EPS Next 3Y25.45%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AVRO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVROBIO INC

NASDAQ:AVRO (6/20/2024, 8:00:00 PM)

After market: 1.45 +0.05 (+3.57%)

1.4

-0.02 (-1.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2024-05-09/amc
Earnings (Next)08-08 2024-08-08/amc
Inst Owners1.37%
Inst Owner Change0%
Ins Owners10.53%
Ins Owner Change0%
Market Cap62.85M
Revenue(TTM)N/A
Net Income(TTM)30.31M
Analysts80
Price Target2.04 (45.71%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)50.45%
Min EPS beat(2)41.76%
Max EPS beat(2)59.15%
EPS beat(4)2
Avg EPS beat(4)-84.15%
Min EPS beat(4)-385.28%
Max EPS beat(4)59.15%
EPS beat(8)3
Avg EPS beat(8)-44.36%
EPS beat(12)5
Avg EPS beat(12)-29.9%
EPS beat(16)7
Avg EPS beat(16)-21.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)50%
EPS NY rev (1m)0%
EPS NY rev (3m)26.53%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.71
P/tB 0.71
EV/EBITDA N/A
EPS(TTM)-1.16
EYN/A
EPS(NY)-0.17
Fwd EYN/A
FCF(TTM)-1.12
FCFYN/A
OCF(TTM)-1.12
OCFYN/A
SpS0
BVpS1.98
TBVpS1.98
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 32.82%
ROE 34.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.45%
ROA(5y)-45.78%
ROE(3y)-65.96%
ROE(5y)-56.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.7%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 26.17
Quick Ratio 26.17
Altman-Z 2.61
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)65.25%
Cap/Depr(5y)96.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.68%
EPS Next Y69.01%
EPS Next 2Y37.49%
EPS Next 3Y25.45%
EPS Next 5Y16.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y46.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.76%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.86%
OCF growth 3YN/A
OCF growth 5YN/A

AVROBIO INC / AVRO FAQ

What is the fundamental rating for AVRO stock?

ChartMill assigns a fundamental rating of 3 / 10 to AVRO.


Can you provide the valuation status for AVROBIO INC?

ChartMill assigns a valuation rating of 1 / 10 to AVROBIO INC (AVRO). This can be considered as Overvalued.


How profitable is AVROBIO INC (AVRO) stock?

AVROBIO INC (AVRO) has a profitability rating of 2 / 10.


What is the earnings growth outlook for AVROBIO INC?

The Earnings per Share (EPS) of AVROBIO INC (AVRO) is expected to grow by 69.01% in the next year.